Virtue Diagnostics Investors

Virtue Diagnostics announced closing US$100 million in Series B funding. Sequoia China and Morningside Ventures jointly led the investment round with ORIZA Holdings. Existing investors Lilly Asia Ventures and PerkinElmer(Revvity) Ventures participated while HAOYUE Capital was the exclusive financial advisor. Virtue Diagnostics is an in vitro diagnostics company that focuses on localized innovation as its strategy, expanding its in vitro diagnostic product business in emerging market countries and regions.